GBT Stock Overview
Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Guerbet SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €27.05 |
| 52 Week High | €40.25 |
| 52 Week Low | €17.02 |
| Beta | 0.76 |
| 11 Month Change | -29.37% |
| 3 Month Change | -21.93% |
| 1 Year Change | 50.95% |
| 33 Year Change | -24.86% |
| 5 Year Change | -48.28% |
| Change since IPO | 172.29% |
Recent News & Updates
Recent updates
Guerbet SA (EPA:GBT) Might Not Be As Mispriced As It Looks After Plunging 29%
Nov 16
Is Guerbet (EPA:GBT) Using Too Much Debt?
Apr 27Further Upside For Guerbet SA (EPA:GBT) Shares Could Introduce Price Risks After 48% Bounce
Feb 29Returns On Capital At Guerbet (EPA:GBT) Paint A Concerning Picture
Feb 11Guerbet SA (EPA:GBT) Screens Well But There Might Be A Catch
Jan 15The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence
Jul 22Guerbet SA's (EPA:GBT) Intrinsic Value Is Potentially 92% Above Its Share Price
Jul 27Analysts Have Been Trimming Their Guerbet SA (EPA:GBT) Price Target After Its Latest Report
Mar 28Is Guerbet (EPA:GBT) A Risky Investment?
Oct 25The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence
Sep 23Is Now The Time To Look At Buying Guerbet SA (EPA:GBT)?
May 27We Think Guerbet (EPA:GBT) Is Taking Some Risk With Its Debt
May 04Is Guerbet SA (EPA:GBT) A Good Fit For Your Dividend Portfolio?
Apr 05Guerbet SA's (EPA:GBT) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Mar 19What Type Of Shareholders Make Up Guerbet SA's (EPA:GBT) Share Registry?
Mar 01When Should You Buy Guerbet SA (EPA:GBT)?
Feb 10
How Much Did Guerbet's(EPA:GBT) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 28Guerbet SA (EPA:GBT) Shares Could Be 25% Above Their Intrinsic Value Estimate
Jan 13Would Guerbet SA (EPA:GBT) Be Valuable To Income Investors?
Dec 23We Think Guerbet's (EPA:GBT) Statutory Profit Might Understate Its Earnings Potential
Dec 11Do Its Financials Have Any Role To Play In Driving Guerbet SA's (EPA:GBT) Stock Up Recently?
Nov 27Shareholder Returns
| GBT | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | -9.4% | 0.07% | -1.2% |
| 1Y | 50.9% | 24.4% | -2.0% |
Return vs Industry: GBT exceeded the French Medical Equipment industry which returned 24.4% over the past year.
Return vs Market: GBT exceeded the French Market which returned -2% over the past year.
Price Volatility
| GBT volatility | |
|---|---|
| GBT Average Weekly Movement | 5.5% |
| Medical Equipment Industry Average Movement | 6.0% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.4% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: GBT has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: GBT's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1926 | 2,920 | David Hale | www.guerbet.com |
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services.
Guerbet SA Fundamentals Summary
| GBT fundamental statistics | |
|---|---|
| Market cap | €341.07m |
| Earnings (TTM) | €32.76m |
| Revenue (TTM) | €840.79m |
10.4x
P/E Ratio0.4x
P/S RatioIs GBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GBT income statement (TTM) | |
|---|---|
| Revenue | €840.79m |
| Cost of Revenue | €211.73m |
| Gross Profit | €629.06m |
| Other Expenses | €596.30m |
| Earnings | €32.76m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 27, 2025
| Earnings per share (EPS) | 2.60 |
| Gross Margin | 74.82% |
| Net Profit Margin | 3.90% |
| Debt/Equity Ratio | 98.3% |
How did GBT perform over the long term?
See historical performance and comparison